Production (Stage)
Intensity Therapeutics, Inc.
INTS
$0.4973
$0.03437.41%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -2.51% | -12.90% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 5.96% | -10.28% | |||
| Operating Income | -5.96% | 10.28% | |||
| Income Before Tax | -5.22% | 9.45% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -5.22% | 9.45% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -5.22% | 9.45% | |||
| EBIT | -5.96% | 10.28% | |||
| EBITDA | -- | -- | |||
| EPS Basic | 0.14% | 13.20% | |||
| Normalized Basic EPS | 0.14% | 13.14% | |||
| EPS Diluted | 50.09% | -73.67% | |||
| Normalized Diluted EPS | 0.14% | 13.14% | |||
| Average Basic Shares Outstanding | 5.36% | 4.32% | |||
| Average Diluted Shares Outstanding | 5.36% | 4.32% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||